FINWIRES · TerminalLIVE
FINWIRES

由于伊朗和平谈判的命运悬而未决,美国股市指数下跌。

-- 美国股指下跌,而原油期货价格上涨,原因是旨在促使伊朗重返巴基斯坦参加第二轮谈判的高风险外交努力仍在进行中。 纳斯达克综合指数下跌0.5%,收于24344.1点;标普500指数下跌0.3%,收于7101.5点。此前,由于美国总统特朗普在上周晚些时候表示,在当前为期两周的停火协议于周二结束前达成伊朗和平协议的可能性很大,纳斯达克综合指数一度创下历史新高。道琼斯工业平均指数下跌0.1%,收于49378.5点。 非必需消费品、通信服务和科技板块领跌盘中。能源和原材料板块则位列涨幅榜前列。 加拿大丰业银行资本市场经济学家德里克·霍尔特周一在一份报告中表示,新一周伊始,市场风险偏好“正在下降”。霍尔特补充说,特朗普周五似乎“严重夸大”了与伊朗达成协议的进展。 据美国有线电视新闻网(CNN)周一报道,特朗普表示,与伊朗的停火协议将于“华盛顿时间周三晚间”结束,并补充说,如果在此之前未能达成协议,他“极不可能”延长停火协议。 据CNN报道,副总统万斯和美国高级官员预计将于周二启程前往巴基斯坦伊斯兰堡,为可能举行的第二轮与伊朗的会谈做准备。一位伊朗高级官员周一告诉路透社,伊朗正在考虑参加和平谈判。此前,伊斯兰堡方面结束了美国对德黑兰港口的封锁,这对于面临广泛袭击威胁的伊朗来说,是重新加入和平进程的一大障碍。 据彭博社报道,美国总统在周一的电话采访中表示,与伊朗的第二轮会谈定于周二开始。 西德克萨斯中质原油期货上涨5%至每桶88.80美元,布伦特原油期货上涨4.8%至每桶95.21美元。 多数美国国债收益率上升,其中10年期国债收益率上涨1.8个基点至4.26%,2年期国债收益率上涨2.5个基点至3.73%,原因是原油价格上涨加剧了通胀担忧。反映出价格上涨的潜在风险,黄金期货下跌1.2%至每盎司4822.1美元,白银期货下跌2.5%至每盎司79.78美元。 公司方面,受中东地缘政治风险恶化的影响,挪威邮轮公司(NCLH)盘中下跌4.2%,成为标普500指数中表现最差的股票之一。 据路透社援引知情人士报道,Meta Platforms (META) 计划于 5 月 20 日启动今年的裁员计划,预计之后还将有更多裁员。这家 Facebook 母公司的股价盘中下跌 2.3%,成为纳斯达克表现最差的股票之一。 据 The Information 援引两位知情人士报道,Alphabet (GOOG, GOOGL) 旗下的谷歌正在与 Marvell Technology (MRVL) 洽谈,共同开发两款针对人工智能推理任务优化的新型处理器。Marvell 的股价盘中上涨 4%,成为纳斯达克涨幅最大的股票。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703